Kohlberg Kravis Roberts

Laureate Education Announces the Commencement of an Underwritten Public Offering by Selling Stockholders

Retrieved on: 
Wednesday, November 16, 2022
Kohlberg Kravis Roberts, Attention, Telephone, Student, Education, Prospectus, Annual report, File, Laureate Education, Strategic Education, Inc., Laureate, University, Security (finance), Sale, Tiger, Form

MIAMI, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Laureate Education, Inc. (NASDAQ: LAUR) (the Company) today announced the commencement of an underwritten secondary offering of 32,842,183 shares of the Companys common stock by certain existing stockholders affiliated with Kohlberg Kravis Roberts & Co. L.P. (the Selling Stockholders).

Key Points: 
  • MIAMI, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Laureate Education, Inc. (NASDAQ: LAUR) (the Company) today announced the commencement of an underwritten secondary offering of 32,842,183 shares of the Companys common stock by certain existing stockholders affiliated with Kohlberg Kravis Roberts & Co. L.P. (the Selling Stockholders).
  • The Company is not selling any shares and will not receive any proceeds from the sale of the shares being offered by the Selling Stockholders.
  • The offering will be made only by means of a written prospectus, including a prospectus supplement, that forms part of the registration statement.
  • The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

Majority of the largest asset managers see declining or stagnant brand awareness for the fourth consecutive year: Global 100 report

Retrieved on: 
Thursday, November 17, 2022
Other Communications, Consulting, Public Relations, Investor Relations, Marketing, Advertising, Communications, Professional Services, Social Media, Other Professional Services, Communication, Baillie Gifford, Marketing, Ares Management, Failure, ESG, Blackstone, Peregrine, AUM, Kohlberg Kravis Roberts, Data, KKR, IPE, Stifel, IMC

Many of the worlds largest asset managers have experienced stagnant or declining corporate brand awareness for the fourth year running, according to Peregrine Communications fourth annual Global 100 report focused on the integrated marketing communications (IMC) performance of the asset management industry.

Key Points: 
  • Many of the worlds largest asset managers have experienced stagnant or declining corporate brand awareness for the fourth year running, according to Peregrine Communications fourth annual Global 100 report focused on the integrated marketing communications (IMC) performance of the asset management industry.
  • Peregrine found that over half of managers (54%) have experienced stagnant or declining brand awareness, a continued trend from 2021, when 52% of asset managers faced the same problem.
  • This Global 100 report focuses on the marketing performance of the world's largest asset management firms as ranked by AUM.
  • Peregrine clients range from start-ups to global investment firms and leading service providers to asset managers.

Cordis Announces Acquisition of MedAlliance, Positioning Itself for Market Leadership in Drug-Eluting Balloon Technology

Retrieved on: 
Tuesday, October 18, 2022
Administration, MIAMI, BTK, Review, Investigational New Drug, Hellman & Friedman, Patient, Peripheral artery disease, Multimedia, History, Technology, Kohlberg, Knee, Acquisition, Industry, Pharmacokinetics, CEO, Sirolimus, KKR, Investigational device exemption, Coronary artery disease, CT pulmonary angiogram, SFA, Kohlberg Kravis Roberts, IDE, Pharmaceutical industry, Medical device, Cordis

By acquiring MedAlliance, Cordis has the potential to serve two million patients globally by 2027 with the SELUTION SLR (Sustained Limus Release) drug-eluting balloon.

Key Points: 
  • By acquiring MedAlliance, Cordis has the potential to serve two million patients globally by 2027 with the SELUTION SLR (Sustained Limus Release) drug-eluting balloon.
  • Cordis will immediately begin co-promotion of MedAlliance's SELUTION SLRdrug-eluting balloon in markets where it is commercially available.
  • "Nearly twenty years ago, Cordis introduced CYPHER, the first drug-eluting stent, transforming cardiovascular treatment for patients around the world," said Shar Matin, Cordis CEO.
  • "Today, we are furthering that legacy of innovation and market disruption with MedAlliance and the first MicroReservoir sirolimus drug-eluting balloon, SELUTION SLR."

LCY Showcases at K 2022 with Advanced Elastomer Portfolio and C.A.R.E. Expertise

Retrieved on: 
Monday, October 17, 2022
BSA, Recycling, High, Polymer, Food packaging, SEBS, LCY, Solution, Plastic, SBCS, PBS, Atomic mass, Senior, Technology, Kohlberg Kravis Roberts, Process, Petro, Medicine, Fermentation, Climate change, Lisa K. Fair McEvers, Efficiency, Fine chemical, Renewable energy

DUSSELDORF, Germany, Oct. 17, 2022 /PRNewswire/ -- LCY Chemical Corp., a leading material science company from Taiwan, showcases its thermoplastic elastomer portfolio at K 2022 to demonstrate how it accelerates material science innovation for a sustainable future. With manufacturing bases in Taiwan, China, and the US, as well as a wide distribution network of warehousing facilities across Europe, LCY joins hands with customers around the world to create the best-in-class material solutions with its in-depth knowledge in material functionality, proprietary hydrogenation process, customized quality products, and trusted local service support.

Key Points: 
  • DUSSELDORF, Germany, Oct. 17, 2022 /PRNewswire/ -- LCY Chemical Corp., a leading material science company from Taiwan, showcases its thermoplastic elastomer portfolio at K 2022 to demonstrate how it accelerates material science innovation for a sustainable future.
  • As a result, manufacturers have been exploring solutions to enhance product appearance and functionality, which may contribute to higher production costs.
  • As an aspiring frontrunner in sustainable elastomer solutions, LCY's elastomer portfolio demonstrates our expertise in C.A.R.E.
  • Visitors are welcome to browse LCY's K Fair booth and discover suitable elastomer solutions.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress

Retrieved on: 
Friday, September 30, 2022
Nervous system, Safety, National Medical Products Administration, Center, Research, Hospital, Achievement, EU, Patient, Clinical trial, Exercise, PHASE 2, AAIC, EUR, Cone Health Women's Hospital, National Institute, DSMB, Center for Drug Evaluation and Research, Kohlberg Kravis Roberts, Company, University of California, San Diego, CDE, VIVA, NIA, AES, Lists of diseases, Doctor of Philosophy, UC, Associate, NMPA, Skin, Annual general meeting, MD, Data monitoring committee, CMO, ADCS, CEO, MCI, Simcere Pharmaceutical, Comprehensive income, Conference, Șaeș, National Institute on Aging, Therapy, Protein, Euronext Amsterdam, Harvard Medical School, BID, Security (finance), Pharmaceutical industry, Medical device, Medical imaging, Health insurance, Neuroscience, Amyloid beta, Neurology

Firstly, we have been able to further de-risk clinical development of varoglutamstat with extremely encouraging safety results from our VIVIAD Phase 2b study.

Key Points: 
  • Firstly, we have been able to further de-risk clinical development of varoglutamstat with extremely encouraging safety results from our VIVIAD Phase 2b study.
  • Vivoryon presented detailed safety data from the VIVIAD study at the Alzheimers Association International Conference (AAIC) in San Diego (July 31 to August 4, 2022).
  • On June 22, 2022, Vivoryon held its Annual General Meeting where all voting items were approved with a large majority.
  • Condensed Statements of Profit or Loss and Other Comprehensive Income for the six months ended June 30, 2022 and 2021

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million

Retrieved on: 
Friday, September 30, 2022
Qualifying investor alternative investment fund, Person, AMERICA, Achievement, Patient, European Economic Area, Investment, Exercise, Urban economics, PHASE 2, Drug development, Ecosystem, EUR, Financial services, Financial Services and Markets Act 2000, Research, Inflammation, Communication, Disease, Council, Market share, Fibrosis, Sale, Securities Act of 1933, Kohlberg Kravis Roberts, Company, Growth, European Union (Withdrawal) Act 2018, KKR, Prospectus, AFRICA, Issuer, CEO, Security (finance), European Parliament, Article, Relevance (Person of Interest), Financial market, Therapy, Risk, Cancer, Offering, Protein, Euronext Amsterdam, Caregiver, Pharmaceutical industry, EU

Vivoryon is pioneering a unique therapeutic approach to overcoming the challenges in Alzheimers disease (AD) drug development.

Key Points: 
  • Vivoryon is pioneering a unique therapeutic approach to overcoming the challenges in Alzheimers disease (AD) drug development.
  • Pursuant to the Offering, the Company will issue 2,054,796 ordinary shares at an offering price of EUR 7.30 per share, amounting to gross proceeds of EUR 15.0 million.
  • As a consequence, the Companys issued share capital will increase to EUR 24,105,278.00 on completion of the Offering, which is expected to occur on October 6, 2022.
  • Hauck Aufhuser Investment Banking acted as sole placement agent in the private placement.

All Seas Capital Backs Zimmer MedizinSysteme

Retrieved on: 
Wednesday, September 21, 2022
Professional Services, Health, Medical Devices, Physical Therapy, Finance, Pharmaceutical, Biotechnology, Acceleration, ESG, Kohlberg Kravis Roberts, Company, Population, Health, Growth, HarbourVest Global Private Equity, Solution, Leadership, SGP, Citibank, KKR, Insurance, Board, Trust, Bankers Trust, Armin, DZ Bank, Renewable energy, Risk management, Financial services, Security (finance), Bank

All Seas Capital Fund I (All Seas Capital), a pan-European private capital fund that provides transformational capital solutions to leading founder- and entrepreneur-owned companies, announces a significant minority investment in Zimmer MedizinSysteme (Zimmer or the Company), one of the leading manufacturers of physiotherapy and aesthetics devices.

Key Points: 
  • All Seas Capital Fund I (All Seas Capital), a pan-European private capital fund that provides transformational capital solutions to leading founder- and entrepreneur-owned companies, announces a significant minority investment in Zimmer MedizinSysteme (Zimmer or the Company), one of the leading manufacturers of physiotherapy and aesthetics devices.
  • Armin Zimmer and Michael Zimmer, co-CEOs of Zimmer MedizinSysteme, said:
    We are thrilled to have found in All Seas Capital a partner that truly understands Zimmers potential and the strength of the family business culture we have built over the past 50 years.
  • Emmanuel Logan-Moll, Managing Director of All Seas Capital, added:
    We are delighted to be partnering with such a well-respected business as Zimmer.
  • All Seas Capital is a pan-European private capital fund that provides flexible long-term financing solutions to leading mid cap companies.

Good Scout Capital Announces Ray Joseph, Rick Moreno, Stacie Olivares, and Qiana Patterson as Senior Advisors to its Growth Equity Fund Promoting Employee Ownership

Retrieved on: 
Thursday, September 8, 2022
Salomon Brothers, State Board of Administration of Florida, BlackRock, Wall Street, Partner (business rank), KKR, UNCTAD Division on Investment and Enterprise, Wilshire Associates, Interior, GSC, Federal Retirement Thrift Investment Board, Investment, KBRA, Goldman Sachs, LinkedIn, Senior, Principal, Good Scouts, Creativity, Kohlberg Kravis Roberts, Treasury, Silicon, Secretary of State of New Jersey, Senior advisor, CalPERS, U.S. Interior Highlands, Barclays, Capitalism, Treasury Department Federal Credit Union, Security (finance), Management, Life insurance

LOS ANGELES, Sept. 8, 2022 /PRNewswire/ -- Good Scout Capital announced the appointments of Ray Joseph, Rick Moreno, Stacie Olivares, and Qiana Patterson to the Senior Advisory Board of its employee ownership growth equity fund - Scout Fund Alpha.

Key Points: 
  • LOS ANGELES, Sept. 8, 2022 /PRNewswire/ -- Good Scout Capital announced the appointments of Ray Joseph, Rick Moreno, Stacie Olivares, and Qiana Patterson to the Senior Advisory Board of its employee ownership growth equity fund - Scout Fund Alpha.
  • With market backgrounds in pension funds, corporate boards, alternative asset management, endowments, and sustainable investing, the Senior Advisors are champions of building out the employee ownership asset class.
  • Good Scout's first growth equity fund focuses on supporting the labor supply chain of large corporations who are in search of ethical and sustainable companies to source from.
  • Qiana Patterson is Managing Partner at NAYAH and a founding Investment Committee Member at The Cap Table Coalition.

Cohn Robbins Holdings Corp. Reminds Shareholders All Redeemed Shares Forfeit Their Bonus Shares to Those Remaining in Transaction

Retrieved on: 
Friday, September 2, 2022
Slate, Online, Transfer, PPF, Blue Harbour Group, High, Economic Policy (journal), Technology, Meeting, NYSE, Kohlberg Kravis Roberts, Safety, Prospectus, Form F-4, Proxy, General Atlantic, Small finance bank, LLP, 1 Manhattan West, Home Credit & Finance Bank, National Lottery (United Kingdom), Skadden, SEC, Investment, National Economic Council, U.S. Securities and Exchange Commission, New, Business architecture, GLOBE, Company, Compliance, Assistant, Form, UKGC, National Economic Council (United States), Founder, URL, Goldman Sachs, Proxy statement, Acquisition, PPF (company), IBM, General partnership, Efficiency, Internet service provider, Security (finance), Online gambling, Allwyn

All CRHC shares that are redeemed will forfeit their bonus shares to those shareholders owning shares that have not been redeemed.

Key Points: 
  • All CRHC shares that are redeemed will forfeit their bonus shares to those shareholders owning shares that have not been redeemed.
  • PPF will have no shareholding in Allwyn Entertainment Ltd, Allwyns UK subsidiary that is its proposed licensee to operate the lottery.
  • Founded and listed on the NYSE in 2020, Cohn Robbins Holdings Corp. is Co-Chaired by Gary D. Cohn and Clifton S. Robbins.
  • Additionally, Cohn Robbins and Allwyn will file other relevant materials with the SEC in connection with the Business Combination.

Axon Names Brittany Bagley as New Chief Financial Officer and Chief Business Officer

Retrieved on: 
Wednesday, August 10, 2022
Brown University, Protective Life, Accounting, Senior, CFO, Facebook, Inc., Twitter, Growth, Board, Director, Goldman Sachs, Kohlberg Kravis Roberts, NASDAQ, CIO, Semiconductor, Software, KKR, Audit committee, Management, Security (finance), Audit, Facebook, Sonos

SCOTTSDALE, Ariz., Aug. 10, 2022 /PRNewswire/ -- Axon (NASDAQ: AXON),the global leader in connected public safety technologies, today announced that it has named Brittany Bagley as its new Chief Financial Officer and the newly created position of Chief Business Officer, effective September 26, 2022.

Key Points: 
  • SCOTTSDALE, Ariz., Aug. 10, 2022 /PRNewswire/ -- Axon (NASDAQ: AXON),the global leader in connected public safety technologies, today announced that it has named Brittany Bagley as its new Chief Financial Officer and the newly created position of Chief Business Officer, effective September 26, 2022.
  • Ms. Bagley replaces Jim Zito, who has been serving as interim Chief Financial Officer since May 4, 2022.
  • Ms. Bagley joins Axon from Sonos (NASDAQ:SONO), where she served as Chief Financial Officer, with oversight of financial, accounting, corporate development, investor relations, real estate, facilities organizations and the CIO and data organizations.
  • Please visit http://investor.axon.com , https://www.axon.com/press , www.twitter.com/axon_us and https://www.facebook.com/Axon.ProtectLife/ where Axon discloses information about the company, its financial information and its business.